Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent.

× No keyword cloud information.

17 in total

1. Improved anticancer effect by combining cytotoxic drugs with an inhibitor of prostaglandin synthesis.

Authors: D A Berstock; J Houghton; A Bennett
Journal: Cancer Treat Rev Date: 1979-06 Impact factor: 12.111

2. Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells.

Authors: M J Droller; P Perlmann; M U Schneider
Journal: Cell Immunol Date: 1978-08 Impact factor: 4.868

3. Indomethacin-sensitive suppressor cells regulate the cell-mediated cytotoxic response to SV 40-induced tumor-associated antigens in mice.

Authors: M Glaser
Journal: Eur J Immunol Date: 1980-07 Impact factor: 5.532

4. Enhancement of anti-cancer activity of cytotoxic chemotherapy with protection of normal tissues by inhibition of P.G. synthesis.

Authors: T J Powles; P Alexander; J L Millar
Journal: Biochem Pharmacol Date: 1978-05-01 Impact factor: 5.858

5. Influence of dosage schedule on the biological characteristics of N-nitrosomethylurea-induced rat mammary tumors.

Authors: D P Rose; B Pruitt; P Stauber; E Ertürk; G T Bryan
Journal: Cancer Res Date: 1980-02 Impact factor: 12.701

6. Flurbiprofen: highly potent inhibitor of prostaglandin synthesis.

Authors: K Nozu
Journal: Biochim Biophys Acta Date: 1978-06-23

7. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate.

Authors: A K Verma; C L Ashendel; R K Boutwell
Journal: Cancer Res Date: 1980-02 Impact factor: 12.701

8. Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin.

Authors: B M Bayer; H S Kruth; M Vaughan; M A Beaven
Journal: J Pharmacol Exp Ther Date: 1979-07 Impact factor: 4.030

Review 9. Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases.

Authors: R N Brogden; R C Heel; T M Speight; G S Avery
Journal: Drugs Date: 1979-12 Impact factor: 9.546

10. Breast cancer and prostaglandins: a new approach to treatment.

Authors: D J Leaper; B T French; A Bennett
Journal: Br J Surg Date: 1979-10 Impact factor: 6.939

10 in total

1. The influence of dietary medium chain triglycerides on rat mammary tumor development.

Authors: L A Cohen; D O Thompson
Journal: Lipids Date: 1987-06 Impact factor: 1.880

2. In vitro effects of eicosanoid synthesis inhibitors in the presence of linoleic acid on MDA-MB-231 human breast cancer cells.

Authors: M Earashi; M Noguchi; M Tanaka
Journal: Breast Cancer Res Treat Date: 1996 Impact factor: 4.872

Review 3. N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors: Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal: Tumour Biol Date: 2015-09-19

4. Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.

Authors: David L McCormick; Jonathan M Phillips; Thomas L Horn; William D Johnson; Vernon E Steele; Ronald A Lubet
Journal: Cancer Prev Res (Phila) Date: 2010-01

Review 5. COX-2 inhibitors for the prevention of breast cancer.

Authors: Louise R Howe; Andrew J Dannenberg
Journal: J Mammary Gland Biol Neoplasia Date: 2003-01 Impact factor: 2.673

6. Anti-inflammation induced by counter-irritation or by treatment with non-steroidal agents inhibits the growth of a tumour of non-detected immunogenicity.

Authors: D O Sordelli; P A Fontán; R P Meiss; R A Ruggiero; O D Bustuoabad
Journal: Br J Cancer Date: 1989-11 Impact factor: 7.640

7. Enhancing effects of quinacrine on development of hepatopancreatic lesions in N-nitrosobis(2-oxopropyl)amine-initiated hamsters.

Authors: F Furukawa; A Nishikawa; T Imazawa; K Kasahara; M Takahashi
Journal: Jpn J Cancer Res Date: 1998-02

8. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.

Authors: John Hayslip; Uzair Chaudhary; Mark Green; Mario Meyer; Steven Dunder; Carol Sherman; Shanta Salzer; Andrew Kraft; Alberto J Montero
Journal: BMC Cancer Date: 2007-12-03 Impact factor: 4.430

9. Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats.

Authors: K Matsunaga; N Yoshimi; Y Yamada; M Shimizu; K Kawabata; Y Ozawa; A Hara; H Mori
Journal: Jpn J Cancer Res Date: 1998-05

10. Influence of esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene in rats on high- and low-fat diets.

Authors: M Noguchi; H Kitagawa; I Miyazaki; Y Mizukami
Journal: Jpn J Cancer Res Date: 1993-10

10 in total